Biogen Inc. (BIIB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Biogen Inc. (BIIB) is up 13.5% since the beginning of the year. At $200 per share, BIIB is trading 3.0% below its 52-week high of $206. Investors who bought $1,000 worth of BIIB shares 5 years ago would now be looking at an investment worth $537.

Biogen Inc. (BIIB) has returned 13.48% so far this year and 57.20% over the past 12 months. Over the last ten years, BIIB has returned -1.36% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Sep 17, 1991, BIIB's average daily return is +0.11%, while the average monthly return is +2.02%. At this rate, an investment would double in approximately 2.9 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jun 2000 with a return of +83.8%, while the worst month was Feb 2005 at -40.5%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 10 months.

On a daily basis, BIIB closed higher 48% of trading days. The best single day was Nov 4, 2020 with a return of +44.0%, while the worst single day was Feb 28, 2005 at -42.6%.

Biogen Inc. has an annualized alpha of 18.65%, beta of 1.03, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 17, 1991.

• This stock captured 126.09% of S&P 500 Index gains and 107.55% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BIIB ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Biogen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biogen Inc. was 89.98%, occurring on Dec 16, 1994. Recovery took 258 trading sessions.

The current Biogen Inc. drawdown is 58.04%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Biogen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Biogen Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.